Obtained a PhD in applied biological sciences working on camel single domain antibodies with expertise in Biochemistry, Molecular Biology, and Biophysics. Started working at Galapagos in 1996, responsible for assay development and Molecular Biology in support for all research projects within Galapagos. After introduction of necessary phenotypic assays for Cystic fibrosis in the company, became responsible for leading the Drug Discovery efforts to identify disease modifying small molecules impacting the CFTR defect. This extensive effort led to the successful identification of several pre-clinical candidates. I am closely involved in all the activities necessary to bring triple combination therapies to patients. Galapagos aims to treat as many CF patients as possible using its CFTR modulators.